

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Pancreatic cancer	Toll-like receptor 7 (TLR7)	<p>Patient sample and mouse studies suggest inhibiting TLR7 could help treat pancreatic cancer. In patient samples, TLR7 expression was greater in invasive pancreatic cancer than in preinvasive pancreatic intraepithelial neoplasias. In a mouse model of pancreatic cancer, oligonucleotide-mediated inhibition of TLR7 prevented malignant progression and stromal expansion. Next steps could include evaluating TLR7 inhibitors in animal models of pancreatic cancer. At least four companies have compounds that inhibit TLR7 in Phase I testing or earlier to treat autoimmune- and inflammation-related conditions.</p> <p><b>SciBX 5(41); doi:10.1038/scibx.2012.1081</b>  <b>Published online Oct. 18, 2012</b></p>	Patent and licensing status unavailable	<p>Ochi, A. <i>et al. J. Clin. Invest.</i>; published online Oct. 1, 2012;            doi:10.1172/JCI63606  <b>Contact:</b> George Miller, New York University School of Medicine, New York, N.Y.            e-mail:  <a href="mailto:george.miller@med.nyu.edu">george.miller@med.nyu.edu</a></p>